Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Black Diamond Therapeutics, Inc. - Common Stock (NQ:BDTX)

2.390 +0.060 (+2.58%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 535,682
Open 2.290
Bid (Size) 2.370 (200)
Ask (Size) 2.500 (800)
Prev. Close 2.330
Today's Range 2.280 - 2.490
52wk Range 1.195 - 4.940
Shares Outstanding 36,213,654
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
From Black Diamond Therapeutics, Inc
Via GlobeNewswire

Performance

YTD
-4.0%
-4.0%
1 Month
-2.8%
-2.8%
3 Month
-4.0%
-4.0%
6 Month
-38.6%
-38.6%
1 Year
+58.3%
+58.3%

More News

Read More
News headline image
Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals ↗
Via Benzinga
News headline image
Black Diamond (BDTX) Q2 Loss Narrows 47% ↗
Via The Motley Fool
News headline image
Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
These stocks have an unusual volume in today's session ↗
Via Chartmill
News headline image
Unusual volume stocks in Thursday's session ↗
Via Chartmill
News headline image
These stocks are the most active in today's session ↗
Via Chartmill
News headline image
What's going on in today's session ↗
Via Chartmill
News headline image
Black Diamond Therapeutics Shares Jump On New Partnership With France-Based Servier: Retail Sentiment Hits Year-High ↗
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
Via Benzinga
News headline image
Wednesday's session: gap up and gap down stocks ↗
Via Chartmill
News headline image
Black Diamond Therapeutics Inks Licensing Pact With French Pharma Firm Servier For Its Early-Stage Cancer Drug Worth Over $700 Million ↗
Via Benzinga
News headline image
Discover the top movers in Wednesday's pre-market session. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Via Benzinga
News headline image
Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
Why Sage Therapeutics Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket ↗
Via Benzinga

Frequently Asked Questions

Is Black Diamond Therapeutics, Inc. - Common Stock publicly traded?
Yes, Black Diamond Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Black Diamond Therapeutics, Inc. - Common Stock trade on?
Black Diamond Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Black Diamond Therapeutics, Inc. - Common Stock?
The ticker symbol for Black Diamond Therapeutics, Inc. - Common Stock is BDTX on the Nasdaq Stock Market
What is the current price of Black Diamond Therapeutics, Inc. - Common Stock?
The current price of Black Diamond Therapeutics, Inc. - Common Stock is 2.390
When was Black Diamond Therapeutics, Inc. - Common Stock last traded?
The last trade of Black Diamond Therapeutics, Inc. - Common Stock was at 04/02/26 04:00 PM ET
What is the market capitalization of Black Diamond Therapeutics, Inc. - Common Stock?
The market capitalization of Black Diamond Therapeutics, Inc. - Common Stock is 86.55M
How many shares of Black Diamond Therapeutics, Inc. - Common Stock are outstanding?
Black Diamond Therapeutics, Inc. - Common Stock has 87M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.